{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:16:48Z","timestamp":1790651808172,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40268-024-00459-5","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T15:42:16Z","timestamp":1714750936000},"page":"155-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Retrospective Assessment of Translational Pharmacokinetic\u2013Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K\/mTOR Inhibitor"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct00854152","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00854126","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Anita","family":"Moein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Y.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Alicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"issue":"5","key":"459_CR1","doi-asserted-by":"publisher","first-page":"FSO306","DOI":"10.4155\/fsoa-2017-0152","volume":"4","author":"AZ Zhu","year":"2018","unstructured":"Zhu AZ. Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology. Future Sci OA. 2018;4(5):FSO306. https:\/\/doi.org\/10.4155\/fsoa-2017-0152.","journal-title":"Future Sci OA"},{"issue":"2","key":"459_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka Jr","year":"2014","unstructured":"Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Ther. 2014;142(2):164\u201375. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.12.004.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"459_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","volume":"20","author":"B Vanhaesebroeck","year":"2021","unstructured":"Vanhaesebroeck B, Perry MWD, Brown JR, Andre F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20(10):741\u201369. https:\/\/doi.org\/10.1038\/s41573-021-00209-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"459_CR4","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s43018-022-00482-y","volume":"3","author":"E Dolgin","year":"2022","unstructured":"Dolgin E. Cancer drug approvals and setbacks in 2022. Nat Cancer. 2022;3(12):1406\u20138. https:\/\/doi.org\/10.1038\/s43018-022-00482-y.","journal-title":"Nat Cancer"},{"key":"459_CR5","unstructured":"2023 Guidance document. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. US Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases. Accessed 8 Jan 2023."},{"key":"459_CR6","unstructured":"2023 Project Optimus. Reforming the dose optimization and dose selection paradigm in oncology. US Food and Drug Administration. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus. Accessed 8 Jan 2023."},{"issue":"1","key":"459_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2007.10.008","volume":"44","author":"L Bueno","year":"2008","unstructured":"Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, et\u00a0al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008;44(1):142\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2007.10.008.","journal-title":"Eur J Cancer"},{"issue":"1","key":"459_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1124\/jpet.108.148189","volume":"329","author":"H Wong","year":"2009","unstructured":"Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, et\u00a0al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009;329(1):360\u20137. https:\/\/doi.org\/10.1124\/jpet.108.148189.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"459_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","volume":"18","author":"J Yang","year":"2019","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26. https:\/\/doi.org\/10.1186\/s12943-019-0954-x.","journal-title":"Mol Cancer"},{"issue":"Suppl 1","key":"459_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4137\/TOG.S30529","volume":"7","author":"DH Josephs","year":"2015","unstructured":"Josephs DH, Sarker D. Pharmacodynamic biomarker development for PI3K pathway therapeutics. Transl Oncogenom. 2015;7(Suppl 1):33\u201349. https:\/\/doi.org\/10.4137\/TOG.S30529.","journal-title":"Transl Oncogenom"},{"key":"459_CR11","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2013.33.e395","author":"TK Owonikoko","year":"2013","unstructured":"Owonikoko TK, Khuri FR. Targeting the PI3K\/AKT\/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ. 2013. https:\/\/doi.org\/10.14694\/EdBook_AM.2013.33.e395.","journal-title":"Am Soc Clin Oncol Educ"},{"issue":"12","key":"459_CR12","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","volume":"10","author":"JJ Wallin","year":"2011","unstructured":"Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, et\u00a0al. GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011;10(12):2426\u201336. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0446.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"459_CR13","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","volume":"22","author":"SO Dolly","year":"2016","unstructured":"Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, et\u00a0al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2016;22(12):2874\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2225.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"459_CR14","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1124\/dmd.112.046052","volume":"40","author":"L Salphati","year":"2012","unstructured":"Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, et\u00a0al. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab Dispos. 2012;40(9):1785\u201396. https:\/\/doi.org\/10.1124\/dmd.112.046052.","journal-title":"Drug Metab Dispos"},{"key":"459_CR15","doi-asserted-by":"publisher","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et\u00a0al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","DOI":"10.1093\/jnci\/92.3.205"},{"issue":"2","key":"459_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdh059.","journal-title":"Ann Oncol"},{"key":"459_CR17","unstructured":"Beal S, Boeckmann L, Bauer R, Sheiner L. NONMEM User\u2019s Guides. (1989\u20132009). NONMEM User\u2019s Guides (1989\u20132009). Elliot City: Icon Development Solutions; 2009."},{"key":"459_CR18","unstructured":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna: R Core Team; 2019."},{"issue":"6","key":"459_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1365-2125.2012.04179.x","volume":"73","author":"GV Goldmacher","year":"2012","unstructured":"Goldmacher GV, Conklin J. The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. Br J Clin Pharmacol. 2012;73(6):846\u201354. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04179.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"459_CR20","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","volume":"26","author":"C Tanaka","year":"2008","unstructured":"Tanaka C, O\u2019Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, et\u00a0al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008;26(10):1596\u2013602. https:\/\/doi.org\/10.1200\/JCO.2007.14.1127.","journal-title":"J Clin Oncol"},{"issue":"7","key":"459_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1124\/dmd.107.019711","volume":"36","author":"S Yamazaki","year":"2008","unstructured":"Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et\u00a0al. Pharmacokinetic\u2013pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos. 2008;36(7):1267\u201374. https:\/\/doi.org\/10.1124\/dmd.107.019711.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"459_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00280-015-2795-7","volume":"76","author":"JW Yates","year":"2015","unstructured":"Yates JW, Dudley P, Cheng J, D\u2019Cruz C, Davies BR. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. Cancer Chemother Pharmacol. 2015;76(2):343\u201356. https:\/\/doi.org\/10.1007\/s00280-015-2795-7.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"459_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/BF01061691","volume":"21","author":"NL Dayneka","year":"1993","unstructured":"Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21(4):457\u201378. https:\/\/doi.org\/10.1007\/BF01061691.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"459_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1124\/dmd.31.5.510","volume":"31","author":"DE Mager","year":"2003","unstructured":"Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003;31(5):510\u20138. https:\/\/doi.org\/10.1124\/dmd.31.5.510.","journal-title":"Drug Metab Dispos"},{"issue":"21","key":"459_CR25","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1021\/jm2009327","volume":"54","author":"DP Sutherlin","year":"2011","unstructured":"Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, et\u00a0al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 2011;54(21):7579\u201387. https:\/\/doi.org\/10.1021\/jm2009327.","journal-title":"J Med Chem"},{"issue":"1","key":"459_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","volume":"21","author":"D Sarker","year":"2015","unstructured":"Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et\u00a0al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0947.","journal-title":"Clin Cancer Res"},{"key":"459_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21031060","author":"C Tarantelli","year":"2020","unstructured":"Tarantelli C, Lupia A, Stathis A, Bertoni F. Is there a role for dual PI3K\/mTOR inhibitors for patients affected with lymphoma? Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21031060.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"459_CR28","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-0975","volume":"17","author":"H Wong","year":"2011","unstructured":"Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, et\u00a0al. Pharmacokinetic\u2013pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation. Clin Cancer Res. 2011;17(14):4682\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0975.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"459_CR29","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1200\/JCO.2012.45.0973","volume":"31","author":"L Claret","year":"2013","unstructured":"Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, et\u00a0al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol. 2013;31(17):2110\u20134. https:\/\/doi.org\/10.1200\/JCO.2012.45.0973.","journal-title":"J Clin Oncol"},{"issue":"14","key":"459_CR30","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1158\/1078-0432.CCR-12-0738","volume":"18","author":"H Wong","year":"2012","unstructured":"Wong H, Choo EF, Alicke B, Ding X, La H, et\u00a0al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res. 2012;18(14):3846\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0738.","journal-title":"Clin Cancer Res"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00459-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00459-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00459-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T10:26:08Z","timestamp":1723199168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00459-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00459-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"7 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Genentech Inc., a member of the Roche group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.M., J.Y.J., M.W., and B.A. are Genentech employees and Roche shareholders. H.W. is Faculty of Pharmaceutical Sciences at the University of British Columbia working under contract with Genentech.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Qualified researchers may request access to individual patient-level data through the clinical study data request platform ().","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Clinical trials (NCT00854152 and NCT00854126) were conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. Prior to enrollment, written informed consent was acquired from all patients, in alignment with the approved protocols from the ethics committees at each study site. All clinical trial information can be accessed through the following website. .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/Consent for publication"}},{"value":"Codes provided in Supplementary Information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Wrote manuscript: A.M., J.Y.J., M.R.W., B.A., and H.W. Designed research: A.M. and H.W. Performed research: A.M. Analyzed data: A.M.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}